BioStock: Stayble’s phase IIb study nears the finishing line

Stayble Therapeutics’ clinical phase IIb study with STA363 takes no break in the summer heat. Approximately 90 per cent of the patients have now completed their 12-month follow-up, which shows that the company has good opportunities to present top-line data during the fourth quarter of this year. The company’s CEO Andreas Gerward tells us more in an interview.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/07/staybles-phase-iib-study-nears-the-finishing-line/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se